During the corresponding time, Viatris Inc recorded a revenue increase by 4.88 % year on year, sequentially revenue grew by 6.82 %. While revenue at the Viatris Inc 's corporate clients
Viatris Inc's Comment on Sales, Marketing and Customers
Viatris operates in over 165 countries and territories, offering a portfolio that includes generics, established brands, and innovative medicines. The company has divested several business segments: its biosimilars portfolio was transferred to Biocon Biologics; its women's healthcare business, including oral and injectable contraceptives, was sold to Insud Pharma, S.L.; its active pharmaceutical ingredient (API) business in India was divested to Matrix Pharma Private Limited; its over-the-counter (OTC) business was sold to Cooper Consumer Health; and rights to the women's healthcare products Duphaston® and Femoston® were divested to Theramex HQ UK Limited and Insud Pharma, S.L. in the United Kingdom. Additionally, commercialization rights in most of the Upjohn Distributor Markets were divested during 2023 and 2024.
In an unexpected turn of events, Viatris Inc. (NASDAQ: VTRS) finds itself embroiled in a legal battle that could have significant implications for the pharmaceutical giant s future. The class action lawsuit, announced by The Gross Law Firm, represents a formidable challenge that Viatris must navigate carefully to ensure its continued growth and shareholder confidence. Understanding the Legal Quagmire On April 23, 2025, The Gross Law Firm issued a notice to Viatris shareholders, inviting them to join a class action lawsuit filed against the company. The deadline to participate in this litigation is set for June 3, 2025, creating a tight window for potential plaintiffs to enlist in the legal proceedings. While...
Viatris Inc. Faces Class Action Lawsuit Amid Deteriorating Receivables Performance Viatris Inc. (NASDAQ: VTRS) is currently under scrutiny following the filing of a class action lawsuit, which has attracted the attention of various law firms, including The Gross Law Firm and Bleichmar Fonti and Auld LLP. Investors who may have incurred losses are being urged to take note of the upcoming deadlines for filing leads in the lawsuit, with a notable date set for June 3, 2025.The lawsuit comes at a challenging time for Viatris as recent financial reports indicate concerning trends in its accounts receivable collection capabilities. The company s receivables turnover ratio stood at 4.17 in the fourth quarter of 2024...
Viatris Inc’s Comment on Sales, Marketing and Customers
Viatris operates in over 165 countries and territories, offering a portfolio that includes generics, established brands, and innovative medicines. The company has divested several business segments: its biosimilars portfolio was transferred to Biocon Biologics; its women's healthcare business, including oral and injectable contraceptives, was sold to Insud Pharma, S.L.; its active pharmaceutical ingredient (API) business in India was divested to Matrix Pharma Private Limited; its over-the-counter (OTC) business was sold to Cooper Consumer Health; and rights to the women's healthcare products Duphaston® and Femoston® were divested to Theramex HQ UK Limited and Insud Pharma, S.L. in the United Kingdom. Additionally, commercialization rights in most of the Upjohn Distributor Markets were divested during 2023 and 2024.
Sources:
Viatris Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Viatris Inc’s corporate clients.
For your research, we’ve provided 9 tables on Viatris Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
112.57 %